The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma

Cancer

Volumn 103, Issue 11, 2005, Pages 2338-2343

  Park, Kyong Hwa ^a   Choi, In Keun ^a   Kim, Seok Jin ^a   Oh, Sang Chul ^a   Seo, Jae Hong ^a   Choi, Chul Won ^a   Kim, Byung Soo ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Biliary tract carcinoma; Chemotherapy; Epirubicin; Uracil plus tegafur (UFT)

Indexed keywords

CISPLATIN; EPIRUBICIN; FOLINIC ACID; UFT;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CARCINOMA; HEPATITIS; HUMAN; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; EPIRUBICIN; FEMALE; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 21044445124     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21041     Document Type: Article

References (17)

1. Li HM, Dou KF, Sun K, Gao ZQ, Li KZ, Fu YC. Palliative surgery for hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2003;2:110-113.
2. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689-1700.
3. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600.
4. Malka D, Boige V, Dromain C, Debaere T, Pocard M, Ducreux M. Biliary tract neoplasms: update 2003. Curr Opin Oncol. 2004;16:364-371.
5. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965-969.
6. Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23:425-428.
7. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9:653-656.
8. Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer. 1995;31A:1594-1598.
9. Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002;13:1192-1196.
10. Findlay M, Cunningham D, Norman A, et al. A Phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5:609-616.
11. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998;16:2877-2885.
12. Muggia FM, Wu X, Spicer D, et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res. 1996;2:1461-1467.
13. Morizane C, Okada S, Okusaka T, Ueno H, Saisho T. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology. 2003;64:475-476.
14. Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res. 1998;4:2085-2088.
15. Mani S, Sciortino D, Samuels B, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999;17:97-101.
16. Chen JS, Yang TS, Lin YC, Jan YY. A Phase II trial of tegafururacil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J Clin Oncol. 2003;33:353-356.
17. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology. 2004;66:138-142.